Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eloquest Healthcare Inc.

Division of Ferndale Healthcare Inc.

Latest From Rimon Therapeutics Ltd.

Convergence: What's Next at the Nexus?

Convergence is the great hope of pharmaceutical and device companies hoping to enter into new high growth markets with differentiated products. Drug-eluting stents turned a stagnant product into a thriving $6 billion market, and now companies are trying to find the next large opportunity that combines devices and drugs. They're looking at many kinds of implantable devices that incorporate biomaterials and drugs to achieve site specific drug delivery, in cardiovascular disease, peripheral vascular disease, ophthalmology, orthopedics, wound healing, and anti-infection.
BioPharmaceutical Medical Device

Rimon Therapeutics Ltd.

Rimon Therapeutics set out to discover polymers that would achieve a therapeutic effect without acting like drugs; that is, they would act locally, wouldn't be metabolized, and wouldn't be soluble. The company has initially focused its product development efforts on wound healing, with two technologies, polymer beads that induce angiogenesis, and a polymer that sequesters matrix metalloproteinases.
Medical Device

Biocoatings: Not Just the Icing on the Cake

The successful commercialization of drug-eluting stents (DES) has done much to pave the way for the biocoating industy. DES not only helped establish a new regulatory body to facilitate device-drug reviews, the FDA Office of Combination Products, they also proved that biocoated devices could take market share from uncoated products, command premium pricing and premium reimbursement.
Medical Device Platform Technologies

Start-Up Previews (3/04)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile groups: Biocoatings, Medical Device Start-Ups in Germany, and Orphan Receptor Drug Discovery. Plus these Start-Ups across Health Care: Alteris Therapeutics Inc., Hepaticus Inc., Semafore Pharmaceuticals Inc. and Synta Pharmaceuticals Corp.
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ferndale Healthcare Inc.
  • Senior Management
  • Tim O'Halla, VP, COO
  • Contact Info
  • Eloquest Healthcare Inc.
    Phone: (877) 433-7626
    780 W. Eight Mile Rd.
    Ferndale, MI 48220